SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, …
Incendia Therapeutics Announces Upcoming Presentations at the European Society for Medical Oncology Congress 2023
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Incendia Therapeutics, formerly Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will have two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2023, to be held in Madrid, Spain October 20-24, 2023. The company will present data on the …
NEXT Oncology and MediLink Team Up on Phase 1 Clinical Trial
FOR IMMEDIATE RELEASE DATE: October 9, 2023 Contact: Lisa Owens, 210-601-6647 NEXT Oncology and MediLink Therapeutics Take “Team Approach” to Next Level on Phase 1 First in Human Clinical Trial in San Antonio (SAN ANTONIO, TX and CAMBRIDGE, MA) October 9, 2023 –– MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for …
Solid Tumors: First-in-human trial of CBX-12 an Alphalex PDC
Ismael Rodriguez Rivera, MD, Medical Oncologist and Clinical Investigator from NEXT Oncology, has conducted a groundbreaking study on a novel therapeutic approach for patients with advanced or metastatic solid tumors. Read the full article, and see the video on the OncologyTube website. iFrame is not supported!
ZielBio to Present Interim Findings from its Phase 1/2
ZielBio, Inc., a clinical stage biotechnology company discovering new treatments for cancer and other serious diseases, will present the first set of clinical data from its lead asset, ZB131, directed against cancer-specific plectin (CSP), during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. In an interim analysis (n=32) of the Phase 1/2 trial, ZB131 demonstrated a favorable safety and tolerability …
Machine Learning in the Diagnosis of Gastric Cancer and Pulmonary Nodule Workup
Machine learning algorithms are increasingly being applied across different areas of medicine and oncology to analyze large data sets and draw conclusions that may otherwise escape the human eye. Indeed, artificial intelligence is slowly eliminating the boundaries imposed by the limited computational ability of humans to the benefit of both clinicians and their patients. At the 2023 ASCO Annual Meeting, …
Worldwide Clinical Trials Expands Site Alliance Collaboration to Support Oncology Trials
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–In response to the growing and ever-changing clinical research landscape and the need to bring innovative treatments to patients faster, Worldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has expanded its Site Alliance Collaboration with new partners across the United States and Europe. Additions include new relationships with NEXT Oncology in Spain and the pan-European Pratia Research Platform, along …
Drug Development in Gastric Cancer: Are We at an Inflection Point?
Gastric cancer drug development has long been thwarted by the challenges of identifying effective targets and developing drugs against the backdrop of the cancer’s inherent tumor heterogeneity.1 Recently, however, advances in our understanding of the molecular underpinnings of gastric cancer and the discovery of actionable biomarkers have led to substantial progress in drug development, leading to improved survival in gastric cancer. …
ABM Announces First Patient Dosed in Phase I Clinical Trial of MEK Inhibitor for Solid Tumor
SAN DIEGO and SHANGHAI, May 5, 2023 /PRNewswire/ — ABM Therapeutics, an innovative clinical-stage biopharmaceutical company, with an emphasis on developing drugs with high blood–brain barrier (BBB) penetration for CNS diseases including brain metastases, today announced that the first patient was successfully dosed with ABM-168 in the United States. MEK (mitogen-activated protein kinase kinase), a key kinase of the MAPK pathway, is frequently activated in …
Video: Expanded Phase 1 Program to the Dallas Area
In this video hosted by Oncology Tube, Anthony Tolcher, MD, discusses Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area. iFrame is not supported!